| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000012640 |
| Receipt No. | R000014771 |
| Official scientific title of the study | Observational study to assess dose-up efficacy of anticholinergic agent on nocturia in overactive bladder patients |
| Date of disclosure of the study information | 2013/12/20 |
| Last modified on | 2016/12/14 (Ver. 6) |
| Basic information | ||
| Official scientific title of the study | Observational study to assess dose-up efficacy of anticholinergic agent on nocturia in overactive bladder patients | |
| Title of the study (Brief title) | Observational study to assess dose-up efficacy of anticholinergic agent on nocturia in overactive bladder patients(Dose Flex Study) | |
| Region |
|
|
| Condition | ||
| Condition | Overactive bladder | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To observe the change of nocturia symptom in OAB patients (IPSS Q7(nocturia score >=3)) |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Change in IPSS Q7 (nocturia score) as change in nocturnal voids |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1)Patients who are regarded as overactive bladder at the start of dosing imidafenacin
2)Patients who have the follow criteria even after administering imidafenacin for more than 4 weeks IPSS Q7(nocturia score) >=3 3)Aged >=20 years |
|||
| Key exclusion criteria | 1)Patients with contraindications for imidafenacin
2)Patients who have current condition of severe difficulty of urination 3)Patients who have history of urinary retention 4)Patients with serious kidney dysfunction 5)Residual urine volume > 50 mL 6)Patients with cancer in bladder, cystoliths, urinary tract infection, recurrent urinary tract infection or interstitial cystitis 7)Patients with polyuria 8)Patients who have administered prohibited substances or done prohibited therapy in the 4 weeks prior to the start of study (excepting operations on urinary and sexual organs) 9)Patients who have been operated on the urinary or sexual organs in the 6 months prior to the start of study 10)Patients with unstable lower urinary tract symptoms 11)Any other patients who are regarded as unsuitable for this study by the investigator |
|||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Yasuyuki Suzuki |
| Organization | Tokyo Metropolitan Rehabilitation Hospital |
| Division name | Department of Medical Care |
| Address | 2-14-1 Tutumidori Sumida-Ward, Tokyo |
| TEL | 03-3616-8600 |
| ysuro@jikei.ac.jp | |
| Public contact | |
| Name of contact person | Yasuyuki Suzuki |
| Organization | Tokyo Metropolitan Rehabilitation Hospital |
| Division name | Department of Medical Care |
| Address | 2-14-1 Tutumidori Sumida-Ward, Tokyo |
| TEL | 03-3616-8600 |
| Homepage URL | |
| ysuro@jikei.ac.jp | |
| Sponsor | |
| Institute | Clinical Research Support Center Kyushu |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kyorin Pharmaseutical Co.,Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | Prospective observational study |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014771 |